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behaviors, medication adherence, clinical factors, and quality of
care. Cross-product terms were speciﬁed to evaluate differential
effectiveness for subjects with differing clinical conditions includ-
ing renal insufﬁciency based on GFR, obesity, longer duration of
diabetes, and older age. RESULTS: A1C was lowered by 1.14
points (95%CI: 1.11–1.17) within one year after initiating new
therapy, but only 30.2% (95%CI: 29.2–31.1%) achieved target
(A1C < 7%). Mean A1C was 9.01 (8.98–9.04) prior to initia-
tion and 7.87 (7.85–7.90) at 3–12 months after baseline. While
baseline disease severity differed across initiators of each thera-
peutic class, there were no statistically signiﬁcant differences in
glycemic lowering across classes, or across clinical conditions.
CONCLUSIONS: Therapy initiation resulted in an impressive
population-level beneﬁt, similar in magnitude to that reported in
randomized trials. Nonetheless, most patients failed to achieve
glycemic targets after initiation possibly because providers had
delayed intensiﬁcation or patients failed to ﬁll earlier prescrip-
tions until they had advanced to very poor control. While no
population-level differences in response by therapy were
detected, in any one patient, differential response by class can
not be excluded. The substantial glycemic response following ini-
tiation suggests that providers are probably choosing therapies
for intensiﬁcation wisely, but that earlier addition of a new agent
may be beneﬁcial.
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OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within a US setting, the cost-effectiveness of
using SMBG. METHODS: A validated, published model for type
2 diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
from major epidemiological studies. Costs of complications were
derived from published sources. From a US third party payer per-
spective, direct costs of diabetes complications and of SMBG
were projected over patient lifetimes. Outcomes were discounted
at 3% annually. RESULTS: Depending on type of treatment
(diet/exercise, oral medications, or insulin), greater glycemic
control with SMBG improved (discounted) QALE by 0.13 to
0.32 QALYs and increased total costs by $2089 to $4661 per
patient. The resulting incremental cost-effectiveness ratios
ranged from $13,848 to $35,880 per QALY gained, and were
well within current willingness-to-pay limits. SMBG was most
cost-effective in patients being treated with oral antidiabetic
medication, and those being treated with insulin therapy. CON-
CLUSIONS: Within the three treatment regimens examined, the
addition of SMBG was associated with increased glycemic
control and with improved clinical and economic long-term out-
comes. The incremental cost-effectiveness ratios were of magni-
tudes typically considered to indicate good value for money.
Additional comparative studies are needed to further assess Util-
ities and other standard outcomes associated with SMBG in
patients with type 2 diabetes.
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OBJECTIVES: Technological innovations may be cost-
increasing and quality-improving (CIQI), cost-saving and
quality-improving (dominant), cost-increasing and quality-
decreasing (dominated), or cost-saving and quality-decreasing
(CSQD). We endeavored to determine how cost-utility analyses
of new medical technologies are distributed across these cate-
gories. METHODS: We systematically searched computerized
databases including MEDLINE, HealthSTAR, CancerLit,
Current Contents and EconLit to identify cost-utility analyses
published in 2002 to 2003. Trained auditors summarized each
study using standardized forms. All costs were converted to 2002
US dollars. RESULTS: We identiﬁed 640 separate published cost
utility analyses. These papers compared 657 interventions
against a standard. Of analyzed interventions, 79.0% (519) were
CIQI, 13.5% (89) were dominant, 6.7% (44) were dominated,
but only 0.8% (5) were CSQD. Among CIQI interventions,
64.6% (335) had a cost-effectiveness ratio (CER) below $50,000
per QALY and 79.0% (410) had a CER below $100,000 per
QALY. Among CSQD interventions, 60% (3) had a CER below
$50,000 per QALY and 2 had a CER above $100,000 per QALY.
CONCLUSIONS: Most published cost-utility analyses are per-
formed on CIQI technologies, and most of these have a CER
below conventionally accepted thresholds. Cost-utility analyses
of CSQD technologies are extremely rare.
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OBJECTIVE: Solid organ transplants are among the most
resource intensive of treatments. There exists only limited knowl-
edge of the current costs of solid organ transplants in Canada
because existing studies were derived from single centres,
included different resource categories, covered different time
periods, and used different cost methodologies. The purpose
study was to derive population-based estimates of the direct
medical costs of kidney, liver, lung and heart transplans in British
Columbia (BC), Canada, from 1995 to 2003. METHODS:
Province wide resource utilization data were extracted from the
BC Transplant Society. This population-based registry includes
records of all persons undergoing solid organ transplantation in
BC. Unit cost data were obtained from publicly available
sources. Health resources categories included inpatient hospital
stays, outpatient visits, physician fees, laboratory and diagnostic
tests and immunosuppressant medications. Mean (standard devi-
ation (SD)) costs were derived separately for the transplant pro-
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cedure and for each of the two years post-transplant and
reported in 2003 Canadian dollars. RESULTS: The mean costs
over all periods was $7706 for 876 persons undergoing kidney
transplant, $28,737 for 257 persons undergoing liver transplant,
$43,719 for 67 persons undergoing lung transplant and $31,152
for 133 persons undergoing heart transplant. The largest com-
ponent for all organs was the cost of the procedure and the initial
hospitalization. The mean (SD) costs in the ﬁrst and second post-
discharge years were, respectively, $21,552 (326) and $11,103
(1260) for kidney, $21,146 (1273) and $8090 (535) for liver,
$27,593 (4801) and $11,426 (1144) for lung and $22,588
(1044) and $9777 (520) for heart. Immunosuppresant medica-
tions comprised the largest single cost component during follow-
up. CONCLUSION: There was six-fold variation in direct
medical costs between the least and most expensive solid organ
transplant procedures. The variation in costs diminished between
programs over the ﬁrst and second years post-transplant.
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OBJECTIVES: To estimate the impact of the following Process
optimization (PO) measures implemented during 2002 on case-
related treatment costs (CRTC) in the ICU of a midsize German
hospital, from the hospital perspective: optimization of diagnos-
tic procedures, standardization of medical devices, improved
management of treatment courses, expansion of renal replace-
ment therapies, and replacement of fentanyl/midazolam (FM) 
by remifentanil/propofol (RP) throughout for analgosedation
within a standardized concept for mechanical ventilation.
METHODS: A retrospective cost-consequence analysis was per-
formed comparing 2 intervals: years 2000–2001 before and years
2003–2004 after PO. Data on baseline characteristics, treatment,
outcomes, and resource utilization (staff, laboratory, medical
need) of the ICU cases came from the routine documentation of
the ICU. Resources were valued in 2004 internal hospital prices.
Differences in CRTC and components between the intervals were
regarded signiﬁcant with a p value <0.05. RESULTS: There were
no signiﬁcant differences in baseline characteristics, distribution
of intensive treatment to monitoring, ventilation days, and case-
related mortality between the totals of 1704 and 2044 cases
treated before and after PO, respectively. CRTC, however, sig-
niﬁcantly dropped by 25% from €2435 before to €1815 after
PO, comprising staff expenses (from €1656 to €1238), labora-
tory cost (from €60 to €41), and cost for medical need (from
€718 to €536). The per-case cost for medical need signiﬁcantly
decreased although 2 of its 14 cost categories showed consider-
able increases: cost for renal replacement therapies were 2.9-fold
after PO due to expansion of this kind of treatment and cost 
for analgosedation were 2.1-fold after PO due to using RP
instead of FM. CONCLUSIONS: The whole PO improved 
the efﬁciency as indicated by signiﬁcantly decreased CRTC at
similar case-related mortality. Using RP throughout for anal-
gosedation of mechanically ventilated patients as an integral part
of a comprehensive PO strategy can result in savings of CRTC
in the ICU.
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OBJECTIVES: Although only 7 pharmacoeconomic and 6 
submission guidelines require partial or total budget impact
analyses (BIA), affordability is becoming a key issue to decision-
makers. Our aim was to review the published BIAs according to
different quality assessment criteria. METHODS: PubMed and
EMBASE were searched for articles with the search terms
“budget impact” or “budget analysis” limited to English lan-
guage. Relevant articles were abstracted by aim, funding, tech-
nology and various issues concerning the analyses. RESULTS: 16
studies were found between 2001 and 2006, the majority pre-
pared for pharmaceuticals, and from the US; however, 50% had
BIA only as complementary calculation to economic evaluations.
In the US, due the dominance of private health insurance, and
in France due to the submission requirements, all studies had BIA
as their main aim. Industry funding was stated for 63%;
however, industry afﬁliation was present for a further 13%. In
accordance with the aim of assisting NHS systems and insurance
companies determine affordability, the payer perspective was
chosen in all of the studies, complemented in a few cases by
patient or societal perspective. Direct medical costs (63%) or
only drug costs (19%) were assessed mostly for one year (44%).
Epidemiological data or rate of adoption was mainly based on
literature and assumptions. Results were reported by resource
type in only 6 (38%) studies, even though this would help to
realize a re-deployment of resources. The majority (56%) were
either cost-saving or had cost-saving scenarios. A sensitivity
analysis was done in only half of the studies for BIAs and in a
further 25% for economic evaluation only. CONCLUSIONS:
Although affordability is major issue in health care ﬁnance, BIAs
are still rare and frequently do not seem to generate independent
analyses. The quality of many studies also fails to reach desired
attributes.
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OBJECTIVES: Data from Sweden (Nyren 1992) shows the
annual frequency of consultations for functional dyspepsia (FD)
to be estimated at 47/1000 population with a costs estimated at
$US113,630/1000 population (1991 dollars). No published data
exists for US based employers on the costs associated with FD.
To assess the economic burden of FD associated with medical
costs and work loss from an employer perspective. METHODS:
A review was conducted using a person-centric database con-
taining costs from multiple large geographically diverse US based
employers between 2001–2004. Claims data included pharmacy,
medical, short- and long-term disability (STD, LTD), sick leave
(SL), and productivity measurements. Comparisons were made
between FD employees (ICD-9 code of 536.8) and employees
without FD. Data were compared for a 12-month period begin-
ning 3 months prior to the ﬁrst diagnosis of FD (the index date).
The average index date from the FD cohort was assigned for the
control group. Multiple regression and Markov modeling tech-
niques along with Charlson Co-Morbidity Index to adjust for
